Together with the findings from the current therapeutic study showing that SNAP-AD5 markedly reduced Aβ and tau pathologies when vaccination was initiated after pathology had already developed in female 3xTg-AD mice, we anticipate similar beneficial outcomes in male 3xTg-AD mice since male 3xTg-AD mice typically exhibit lower levels of Aβ and tau pathology than females (Barber et al., 2024). The gene discussed is MAPT; the disease is Alzheimer disease.